Methamphetamine-dependence
2
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
3 programs1
Ibudilast 20mgPhase 11 trial
Contingency ManagementN/A1 trial
Contingency Management-ARTN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Oregon TherapeuticsIbudilast
Angeles TherapeuticsIbudilast 20mg
Angeles TherapeuticsContingency Management
Angeles TherapeuticsContingency Management-ART
Clinical Trials (4)
Total enrollment: 237 patients across 4 trials
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
Start: May 2019Est. completion: Oct 2025176 patients
Phase 2Completed
Safety Interaction Trial Ibudilast and Methamphetamine
Start: Jan 2011Est. completion: Mar 201311 patients
Phase 1Completed
Inflammation in Methamphetamine and STIs (IMSTI)
Start: May 2022Est. completion: Jun 202730 patients
N/AActive Not Recruiting
Contingency Management for PrEP Adherence and/or Methamphetamine Use
Start: Mar 2021Est. completion: Aug 202120 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.